Global
EN CN
News
Strive forward with partners and pursue dreams
Leadingtac Announces First Healthy Volunteer Dosed in a Phase 1 Clinical Program of LT-002, a Potentially best-in-class IRAK4 degrader
2024-06-26
Shanghai Leadingtac Pharmaceutical Co., Ltd. (hereinafter referred to as "Leadingtac"), a clinical-stage biopharmaceutical company focused on the development of protein degrader for the treatment of chronic inflammatory and autoimmune diseases, announced on June 25th that the first healthy volunteer has been dosed in Phase 1 trial evaluating the safety, pharmacokinetic profile and food effects of LT-002.
Learn More
LeadingTac: Leading the Targeted Protein Degradation Track to Make Global Innovative Innovative Drugs
2024-02-28
Recently, Dr. Yan Feng, the founder of LeadingTac, was selected as one of the "Pearl Leading Talent" in Pudong New Area in 2023 after passing the strict evaluation by the Talent Expert Group of Pudong New Area Committee for his targeted protein degradation project.
Learn More
Big congratulations to Dr. Yan Feng of Leaddingtac was awarded with one of the first few of "Pearl Leading Talent" in Pudong New Area
2023-12-12
On December 6, 2023 Pudong International Talent Port Forum, with the theme of "Leadership, Gathering Momentum and Leap", was held at the Zhangjiang Science Hall. The first batch of "Pearl Program" tal
Learn More
Leadingtac Announces CDE Approval of Phase I Clinical Trial for LT-002 for the treatment of Hidradenitis Suppurativa
2023-10-25
Following the U.S. FDA approval of LT-002 for the treatment of Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) on May 24, 2023 (NCT06082323), Leadingtac received the clearance from the CDE of
Learn More
Leadingtac received the award "Shanghai 2023 technology innovation funds for small and medium-sized enterprises" project
2023-09-13
Recently, Shanghai Municipal Science and Technology Commission announced the "List of Projects of Shanghai 2023 Technology Innovation Funding Program for Small and Medium-sized Enterprises (SMEs)". Af
Learn More
You may proceed!Leadingtac receives IND clearance to Conduct a Phase I study of LT-002, a world second-in-class IRAK4 degrader
2023-05-24
Shanghai Leadingtac, a rapidly expanding biotechnology company, focusing on the development of protein degrader therapeutics, today announced the U.S. Food and Drug Administration (FDA) has cleared it
Learn More
Zhangjiang Science Investment Family|Leadingtac: Contributing to China's New Drug Development in Zhangjiang
2023-04-18
Zhangjiang Science Investment Family|Leadingtac: Contributing to China's New Drug Development in ZhangjiangLooking back again, Yan Feng, founder of Vπ Zhangjiang Science Investment Ecological Fund
Learn More
Leadingtac was selected as one of the "KPMG China's 2nd Biotechnology Innovation 50 Companies List".
2023-04-07
On April 7, 2023, KPMG China held the second "Biotechnology Innovation 50 Companies List Launch and Award Ceremony" in Beijing, Shanghai and Shenzhen offices, online and offline. After strict selectio
Learn More
First in China: Leadingtac's IND application for IRAK4 degrader accepted by US FDA
2023-03-27
On March 28, 2023, Shanghai Leadingtac Pharmaceutical Co., Ltd. (hereinafter referred to as "Leadingtac Biotech") announced that it has officially submitted an IND clinical trial application to the U.
Learn More
Dr. Zhengqing Ye was selected as one of the "Shanghai Pujiang Talent Program" in 2022
2022-11-18
In October 2022, the Shanghai Science and Technology Commission awarded the honorary certificate of being selected as one of the "Shanghai Pujiang Talent Program Projects" for 2022.
Learn More
Total 17 12
Company Mailbox
Incoming Email
Official Account